The present invention relates to a synthetic promoter capable of controlling the expression of a target gene at various locations in the genome of an acid-resistant strain, and more particularly to a synthetic promoter including a core promoter derived from an acid-resistant strain and an upstream activating sequence (UAS) element serving as an enhancer. When the present invention is applied to a variety of genetic and metabolic engineering techniques for acid-resistant yeast, various metabolic networks can be configured as desired while controlling the expression level of the target gene, so a method of producing various metabolites using acid-resistant yeast is provided, and the cost of producing the metabolites can be greatly reduced depending on the properties of the acid-resistant yeast.

An engineered bacterium for producing ethanol from one or more carbohydrates is disclosed. The bacterium can be made by (a) inactivating within a Lactobacillus casei bacterium one or more endogenous genes encoding a lactate dehydrogenase; or (b) introducing into a Lactobacillus casei bacterium one or more exogenous genes encoding a pyruvate decarboxylase and one or more exogenous genes encoding an alcohol dehydrogenase II; or (c) performing both steps (a) and (b). The resulting engineered bacterium produces significantly more ethanol than the wild-type Lactobacillus casei bacterium, and can be used in producing ethanol from a substrate such as biomass that includes carbohydrates.

Provided herein is a genetically engineered microorganism comprising knock-in of DNA at an acetolactate decarboxylase gene locus. Replacement of the acetolactate decarboxylase gene with DNA encoding one or more native or nonnative enzymes confers certain advantages, including fermentation stability and increased production of native and nonnative products from gaseous substrates.

A method to express myoglobin in a fungus is described. The method includes optimizing a codon for a fungal host (e.g., Trichoderma reesei), inserting the optimized codon into a plasmid (e.g., a pTrEno plasmid or one of its derivatives), and ultimately collecting the secreted myoglobin from a feeding media in response to the myoglobin being expressed extracellularly. Optionally, the myoglobin is purified.

A transformant obtained by introducing a DNA of (a1), (a2), or (a3) below, and (b) an alcohol dehydrogenase gene, into a bacterium of the genus Hydrogenophilus, can efficiently produce isobutanol utilizing carbon dioxide as a sole carbon source. (a1) DNA which consists of a base sequence of SEQ ID NO: 1; (a2) DNA which consists of a base sequence having 90% or more identity with SEQ ID NO: 1, the DNA encoding a polypeptide having 2-keto-acid decarboxylase activity; (a3) DNA which hybridizes with a DNA consisting of a base sequence complementary to SEQ ID NO: 1 under stringent conditions, and which encodes a polypeptide having 2-keto-acid decarboxylase activity.

A transformant obtained by introducing a DNA of (a1), (a2), or (a3) below, and (b) an alcohol dehydrogenase gene, into a bacterium of the genus Hydrogenophilus, can efficiently produce isobutanol utilizing carbon dioxide as a sole carbon source. (a1) DNA which consists of a base sequence of SEQ ID NO: 1; (a2) DNA which consists of a base sequence having 90% or more identity with SEQ ID NO: 1, the DNA encoding a polypeptide having 2-keto-acid decarboxylase activity; (a3) DNA which hybridizes with a DNA consisting of a base sequence complementary to SEQ ID NO: 1 under stringent conditions, and which encodes a polypeptide having 2-keto-acid decarboxylase activity.

The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patients internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding an improved leucine catabolism enzyme with higher activity and/or specificity for leucine over other branched chain amino acids, such as isoleucine or valine. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of leucine, isoleucine, and/or valine using the pharmaceutical compositions disclosed herein.

Yeast strains and fermentation process for producing D-lactic acid and L-lactic acid are disclosed with higher titer, higher yield, shorter time, lower pH, and higher average specific productivity.

The present invention relates, at least in part, to the production of resveratrol from 4-coumaric acid. The production can be mediated in a transgenic Saccharomyces cell.

The disclosure relates to a tyrosol-producing recombinant Escherichia coli and a construction method and application thereof and belongs to the technical field of bioengineering. The Escherichia coli undergoes heterologous expression of a codon-optimized Saccharomyces cerevisiae pyruvate decarboxylase gene ARO10*. According to the recombinant Escherichia coli, five sites of a lacI site, a trpE site, a pabB site, a pabA site and a pykF site of an Escherichia coli genome are deleted, and at the same time, the ARO10* gene is integrated at each site of the five sites to obtain a strain containing multiple copies of the ARO10* gene. On the basis of the above recombinant strain, the ARO10* gene is randomly integrated at multiple sites, and it is found that a strain with high-yield production of tyrosol can be obtained by inserting the ARO10* gene at a yccX site. Fermentation using this strain does not require inducers or antibiotics. After fermentation is carried out for 48 hours, the yield of tyrosol can reach 32.3 mM.